investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
58k on the bid at $1.45
10K shares on the bid at $1.40
I think your right.
We have buyers(21K shares on the bid at $1.39). Are investors starting to take notice of this beaten down, but seemly turning it around, company?
Larson should have wait until the bump to sell some of his aquired shares. Sold at $1.31.
News and Volume= a slight bump.
Can this be the turn needed to move Navb higher?
Heavy volume today.
Shorts pushing down pps?
Accumulation?
Hopefully we see volume precede price.
In the last 7 months, since the R\S, saw the share price rise about 20%, only to have it return to the pre-R\S price today. Ebola news rise negated by the Roche news, on the down side. I know, down day for the market also.
Which way does INO go from here? and Why?
A little profit-taking today, followed by an end of the day (low volume) walk down on the pps.
Buying opportunity Monday, if this opens near today's close.
Too bad, for them, someone's stop-loss at $1.96 was tripped today. Risky to use stop-losses on bio's with low volume.
Any comments on the price action today and the close of $2.16, seemingly without any news.
Seems to be resistance levels close by, according to your read of the TA.
RXII up 15% today.
3 phaseII trials currently underway and data should be released in the next few months.
Shorty will try to push the pps down close to EOD.
Hold tight.
Nice run this am.
Do we have any short covering today.
Run seems to be without news. I know RXII is way undervalued, at this level.
Anyone?
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical Trial Site for Neuro-Spinal Scaffold
http://finance.yahoo.com/news/invivo-therapeutics-announces-university-pittsburgh-130000534.html
NVIV: Zacks Rank #2 (Buy)
Can InVivo Therapeutics Holdings (NVIV) Run Higher on Strong Earnings Estimate Revisions?
"The stock has also started to move higher lately, adding 45.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future."
http://finance.yahoo.com/news/invivo-therapeutics-holdings-nviv-run-112604994.html
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for Neuro-Spinal Scaffold.
This site is in my area and I do business with this institution. I don't know Dr. Raslan, but very nice to have a site in my area.
http://finance.yahoo.com/news/invivo-therapeutics-announces-oregon-health-130000498.html
INO is definitely a long term investment. Still a lot of potential here. Chances are any short term news will be a bonus that may move the pps up for a while.
Pre-clinical news moves the pps today, but pps may be stuck near $10, for the time being.
Good luck to the longs, I will be watching.
I definitely agree that RXII is Undervalued and is a great bargain at or near $1.80 pps.
I think you have shareholders that have purchase shares and many have added at these recent prices, and are holding them tight. The volume has been low since these shareholders are holding their shares looking for more positive news from the 3 phase 2 trials currently underway.
Share price should appreciate as more positive data is released.
"These highly statistically significant Phase 3 ANNEXA-A data demonstrate that andexanet alfa has the potential to be the first agent approved as a universal Factor Xa inhibitor antidote. We anticipate filing a Biologics License Application with the FDA for Accelerated Approval at the end of 2015," said John T. Curnutte, M.D., Ph.D., executive vice president of research and development for Portola.
The two small phase 3 trials are going well and the 1st trial reported good results described above. But both of the small phase 3 trials have been on health volunteers. Will and how will Portola test andexanet alfa on actual patients with critical bleeds on anticoagulation therapy?
In the statement above, made by the executive vice president, it says that the filing with the FDA for the BLA will not happen for a year.
The need is certainly there for this product, but what will the FDA require for approval?
I still believe that DVAX is a good long term play, but I guess it goes to show that a RS and a shelf registration can have a negative effect on the pps.
This may all turn around eventually, but I trying to find the bottom to this dip. $12.50 is the 52 week low, so I'm predicting the bottom is somewhere between today's price and $12.50.
Perkin78,
This is a post I made on August 11, 2014.
The only statement, I believe that is incorrect is that INO did not have the funding to do the phase III, trial, but I believe they have a shelf registration in place that could fund such a trial or they could raise additional funds for that purpose.
From August 11, 2014
I believe investors might have been looking for the release of additional clinical information and/or information regarding a partnership to develop VGX-3100.
Dr. Kim only mentioned partnership in passing at the end of the presentation, but reaffirmed that INO has the funding to do the phase 3 trial on their own. Are his statements part of a negotiation strategy or:
The following was taken from my post after the phase 2 data:
Dr. Kim has made no secret that his primary focus is getting VGX-3100 into a phase 3 trial and I think he has a preference to run the trial without a partner. He wants to retain complete control. I believe doing the clinical trial without a partner brings undo risk to INO and the stock. Even the very largest pharma companies often partner to reduce the risk of phase 3 trials and potential market approval.
Still long, but hoping Dr. Kim and the board make the best decision with regard to partnering.
Looks like we are stuck within a trading range of $.98- $1.02.
Without additional news on the first trial patient or any new patients enrolling, I think we maybe stuck here.
Not a bad scenario, but it's hard to be patient, and would either prefer:
1. A drop in share price, not do to negative news, to load more shares.
2. Increasing share price to make money.
Would love to see the scaffolding alone improve prognosis of the SCI patients. That in the end would be good for everyone.
I guess we'll just have to wait for the news.
That Thursday drop to $1.98 was so fast, it doesn't even register on the 5 day chart.
The two teens not a bad place to buy shares. Thought this might continue to run from a couple of weeks ago, but hope this is just a buying opportunity.
Do we know which way this is headed, in the short term?
I guess we will get an update on Wednesday.
I know DVAX has a fair amount of cash, but the phase 3 trial and potential launch of Heplisav being a couple of years away, does anyone see a potential for a capital raise here?
Float now at just over 22 millon shares.
Let's see how the market reacts to the RS. Share price only down slightly after hours.
Do we see a buying opportunity next week?
Low volume for most of the last couple of weeks.
Most investors are holding their shares to see if the positive 3 month outcomes, for the first 2 patients, continue for subsequent patients in the trial.
I will follow the trial as it continues to provide data to support moving RXI-109 on to a phase 2b or phase 3 trial.
As I see positives coming from all of the phase 2 trials, I will continue to buy shares on the dips.
Dynavax is probably a long term play to get the biggest return.
Data read out sometime in 2016, probably will be a positive for the pps
Heplisav approval probably around the end of 2016 or early 2017.
Currently, as listed on ihub, 81% institutional ownership.
August 7, 2014 Update:
Recent Developments
On April 15, 2014, we announced the initiation of a new Phase 3 clinical trial of HEPLISAV-B (known as HBV-23). This safety and immunogenicity study was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013. This study is intended to significantly increase the number of vaccinated subjects and provide a sufficiently-sized safety database for the FDA to make a final determination regarding the safety and immunogenicity of the product. The study is a Phase 3, observer-blinded, randomized, active-controlled, multicenter trial at approximately 40 sites in the U.S. Approximately 8,250 adult subjects between the ages of 18 and 70 will be randomized in a 2:1 ratio to receive a 2-dose series of HEPLISAV-B or a 3-dose series of a control vaccine, Engerix-B. Enrollment will be stratified by site, age group and type 2 diabetes mellitus status.
The co-primary objectives of the study are: (1) to evaluate the overall safety of HEPLISAV-B with respect to clinically significant adverse events and (2) to demonstrate the noninferiority of the seroprotection rate ("SPR") induced by HEPLISAV-B compared with Engerix-B at week 28 in subjects with type 2 diabetes mellitus. All subjects will be evaluated for safety through study week 56. All potential autoimmune events will be reviewed by a Safety Evaluation and Adjudication Committee and overall safety will be monitored by a Data and Safety Monitoring Board. Enrolled was completed by September 23rd, 2014,and all follow-up will be completed by the fourth quarter of 2015. We estimate the external costs of the study to be in the range of $50-55 million. Market for Heplisav-B could be as high as $700 million dollars.
On August 7, 2014, we announced safety and pharmacodynamic results from clinical studies of our asthma drug candidate partnered with AstraZeneca and our systemic lupus erythematosus (SLE) drug candidate partnered with GlaxoSmithKline, as follows:
In a Phase 1 study, 4 weekly doses of a TLR9 agonist, AZD1419, or placebo were delivered by inhalation to 45 healthy volunteers. Ascending doses up to 15.4 mg/week for 4 weeks were well tolerated and no serious adverse events were observed in treated subjects. Secondary endpoints assessing pharmacodynamics were met, with dose-dependent induction of interferon-regulated genes in sputum and blood cells. Based on these results, Dynavax and its collaboration partner, AstraZeneca, are evaluating protocols for a clinical trial in patients with asthma.
In a Phase 1b/2a study, the safety and pharmacodynamics of a bifunctional TLR7 and TLR9 inhibitor, DV1179, were assessed in 52 SLE patients screened for elevated expression of interferon-regulated genes. DV1179 did not meet the primary or secondary pharmacodynamic endpoints related to reduction in interferon alpha-regulated genes. Doses up to 60 mg/week for 8 weeks were well tolerated. The most common adverse events were injection site reactions. GSK will review the data package and determine whether to exercise its option to license DV1179.
A little pull back today after a nice uptrend. Volume continues to be good.
Haven't been following the short ratio, but seems to around 17%.
Current price per share at the low end, historically.
Don't know when and why anyone would expect the price to go much lower here or in the near future.
DVAX share up 10% in the last 5 days and,
Up 18% in the last month.
Day by day moving toward data, then approval of Heplisav.
2%+ today on light volume.
Small trades through out the day.
I think most LT share holders (like me) are looking for more upside after the positive 3 month pictures.
Finished at the HOD: $2.13. Good but I'm holding for the 1 year price target of: $10.17, at least.
Let's keep it going.
So we get a 10% pop today and nice AH trade.
Looking for the pps to stay above $2 and continue upward.
Volume picking up since the announcement (October 15th) of the 1st patient in the trial: Averaging 1.5 million shares traded.
As long as the news continues to be positive and the trial continues, we should see the pps appreciate.
I think the current shareholders aren't necessarily eager to sell their shares, and are willing to wait for a bigger payoff as the trial progresses. The Buy/Sell ratio was about 7 to 2 today.
Of course, Frank Reynolds, may still be selling, but if the volume stays up, hopefully he either will liquidate his remaining shares or decide to hold his shares as the pps moves up.
I am definitely going to see how this 1st human trial plays out, before I make any decisions about selling my shares.
I appreciate the update and your thoughts.
Looking for good things over the next few years, from RXII.
Long way to go yet, but 4-5% per day is a good start.
Continued positive results, at 3 months, in the clinical trials will continue to move this forward.
Closed at the HOD: $1.80.
Hopefully we will continue the climb back to at least the price before the bungled/misinterpreted September presentation.
With the early 3 month data, we should be on the road to higher prices, IMHO.
Total of 93,000 shares buys posted after hours
I agree, that a reverse split does not have to have a negative effect on the pps. But if combined with dilution, and a lack of news/communication from management, investors can get discourage, particularly if any or all of these events blunts the effect on pps of positive news.
I have planned to be in ONCS for the long term if:
1. ONCS meets the milestones it has committed to attaining in 2014.
2. I agree with the decisions and rationale for these decisions management makes re: reverse split, dilution, and partnerships. Just to name a few.
I still hold a fair amount of ONCS stock, and had a nice run with INO,LAST YEAR.
Since INO PPS is down 15% for the year and almost 30% in the last six months, yes I have been flushed out of INO. I see few potential major catalysts upcoming to move the stock forward and I haven't agreed with some of management's recent decisions, so I have been looking at other investments.
I would hate to see ONCS follow INO's path, in 2014, and end up with a negative share price performance, similar INO this year.
Has INO's stock price and valuation dropped since the dilution and R/S of earlier this year?
Yes, it has. Of course there are other factors at play with the stock, but the fact is the stock price is down since the dilution and reverse split. I guess that is why, in this case, some people think reverse splits can have a negative effect on pps and valuation.
Absolutely,
It would be nice if you had bothered looking at the string of the conversation regarding the path ONCS might chose to take moving forward vs. the path INO took.
I do not believe that the unnecessary dilution and the R/S was a positive decision for INO, and thus the stock price, split adjusted, and the market capitalization both took a hit.
I was hoping ONCS would not follow INO, in that way, and thus not effective valuation and pps negatively.
Delisting
No Communication by management
Manny where are you?